DBV Technologies (NASDAQ:DBVT) Stock Gets Price Target Reduction from Citizens Jmp

DBV Technologies (NASDAQ:DBVT) had its target price reduced by Citizens Jmp from $55.00 to $47.00 in a report published on Thursday,Benzinga reports. They currently have a market outperform rating on the stock.

A number of other research analysts also recently commented on the company. Cantor Fitzgerald reissued an “overweight” rating on shares of DBV Technologies in a report on Thursday, September 10th. Citigroup restated a “market outperform” rating on shares of DBV Technologies in a report on Thursday. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of DBV Technologies in a research report on Thursday, October 15th. Finally, Wall Street Zen cut DBV Technologies from a “hold” rating to a “sell” rating in a research note on Saturday, July 4th. Five equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $45.25.

DBV Technologies Price Performance

NASDAQ:DBVT opened at $9.49 on Thursday. The firm has a 50-day moving average of $11.53 and a two-hundred day moving average of $16.93. The stock has a market cap of $596.73 million, a P/E ratio of -3.15 and a beta of -1.04. DBV Technologies has a 1-year low of $8.63 and a 1-year high of $26.18.

DBV Technologies (NASDAQ:DBVT) last announced its earnings results on Wednesday, October 28th. The company reported ($0.70) earnings per share for the quarter, missing the consensus estimate of ($0.26) by ($0.44). DBV Technologies had a negative net margin of 5,392.17% and a negative return on equity of 120.95%. The business had revenue of $1.60 million for the quarter, compared to analyst estimates of $0.56 million. As a group, equities analysts expect that DBV Technologies will post -2.22 earnings per share for the current year.

Institutional Trading of DBV Technologies

Several institutional investors and hedge funds have recently bought and sold shares of the company. ADAR1 Capital Management LLC bought a new stake in shares of DBV Technologies in the 1st quarter valued at approximately $21,159,000. Perceptive Advisors LLC acquired a new stake in shares of DBV Technologies during the 1st quarter valued at approximately $20,146,000. Elmind Capital LP bought a new position in DBV Technologies during the first quarter worth $5,536,000. Vivo Capital LLC lifted its stake in DBV Technologies by 8.4% during the first quarter. Vivo Capital LLC now owns 2,667,569 shares of the company’s stock worth $55,726,000 after purchasing an additional 205,943 shares during the last quarter. Finally, Dorsey Wright & Associates acquired a new position in DBV Technologies in the first quarter worth $2,142,000. Institutional investors and hedge funds own 71.74% of the company’s stock.

Trending Headlines about DBV Technologies

Here are the key news stories impacting DBV Technologies this week:

• Positive Sentiment: DBV submitted a Biologics License Application to the FDA for the VIASKIN Peanut Patch in children ages 4–7 and requested Priority Review. The company also said it is accelerating commercial preparations, supporting the potential value of the product if approved. DBV Technologies Reports Third Quarter 2026 Financial Results and Business Update
• Positive Sentiment: HC Wainwright raised its FY2028 earnings estimate to $1.25 per share from $1.15 and maintained a Buy rating, reflecting greater confidence in the company’s longer-term commercial outlook.
• Positive Sentiment: Guggenheim maintained a Buy rating and lowered its price target to $46 from $51. Despite the reduction, the target implies substantial upside from recent trading levels.
• Neutral Sentiment: DBV reported $165.7 million in cash and cash equivalents as of September 30, which management said should fund operations into the third quarter of 2027. However, the company remains dependent on future execution and regulatory progress.
• Negative Sentiment: Third-quarter EPS was a loss of $0.70, substantially worse than the consensus loss estimate of $0.26. Revenue of $1.60 million exceeded the $0.56 million estimate, but the company continues to report deeply negative profitability metrics. DBV Technologies Report Wider Q3 Loss, Advances Peanut Allergy Patch Toward Potential Launch
• Negative Sentiment: DBV disclosed heightened going-concern risk as liquidity constraints increase the possibility of dilutive financing. A new equity raise could pressure existing shareholders and likely contributes to the stock’s weakness. DBV Technologies Faces Heightened Going-Concern Risk
• Negative Sentiment: Citizens lowered its price target to $47 from $55 while maintaining a Market Outperform rating, citing third-quarter manufacturing risk. The target reduction reinforces concerns about execution ahead of a potential launch.

DBV Technologies Company Profile

DBV Technologies SA (NASDAQ: DBVT) is a clinical-stage biopharmaceutical company focused on developing treatments for food allergies and other immune-mediated conditions. The company’s approach is based on epicutaneous immunotherapy, which is designed to deliver small amounts of an allergen through the skin to help desensitize the immune system.

DBV Technologies’ lead product candidate is Viaskin Peanut, an investigational patch intended to treat peanut allergy, particularly in children.